Contineum can now sell up to $100 million of Class A stock through Leerink Partners LLC, and its dilution example shows $7.18 a share lost at a $15.34 price. The company has also deferred two programs until it obtains funding.
Latest Contineum Therapeutics news
We have not published a story on Contineum Therapeutics yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $14.7 million, plus short-term investments of $221.8 million, $236.6 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Contineum Therapeutics
What is the ticker symbol of Contineum Therapeutics?
Contineum Therapeutics, Inc. trades under the ticker CTNM on NASDAQ.
Where is Contineum Therapeutics listed?
Contineum Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Contineum Therapeutics?
The SEC Central Index Key (CIK) for Contineum Therapeutics, Inc. is 1855175. Its filings are on SEC EDGAR.
How many shares does Contineum Therapeutics have outstanding?
23,099,173 shares as of 2025-10-27, per the cover page of its 10-Q filed 2025-10-30.
Which country or territory is Contineum Therapeutics listed under?
Our directory records Contineum Therapeutics, Inc. under United States.
What does Contineum Therapeutics do?
Our directory classifies Contineum Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Contineum Therapeutics?
The ISIN recorded for Contineum Therapeutics, Inc. is US21217B1008.
Does aibio.space cover Contineum Therapeutics?
aibio.space lists Contineum Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Contineum Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Contineum Therapeutics profitable?
Contineum Therapeutics, Inc. reported a net loss of $60.0 million for the fiscal year ended Dec 31, 2025, and used $55.3 million of cash in operations, per its annual report to the SEC.
How much does Contineum Therapeutics spend on research and development?
$51.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Contineum Therapeutics have?
$236.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Contineum Therapeutics (CTNM) stock news?
Our latest story on Contineum Therapeutics, dated Mar 5, 2026: "Contineum Therapeutics amends share sales deal, registers up to $100 million". Contineum can now sell up to $100 million of Class A stock through Leerink Partners LLC, and its dilution example shows $7.18 a share lost at a $15.34 price. The company has also deferred two programs until it obtains funding. Source.
What is Contineum Therapeutics's latest stock offering or financing news?
Our latest financing story, dated Mar 5, 2026: "Contineum Therapeutics amends share sales deal, registers up to $100 million". Contineum can now sell up to $100 million of Class A stock through Leerink Partners LLC, and its dilution example shows $7.18 a share lost at a $15.34 price. The company has also deferred two programs until it obtains funding. Source.
Who were the underwriters or placement agents on Contineum Therapeutics's offering?
From our story: The shares are sold at the market through Leerink Partners LLC as sales agent. Source.
Investor discussion: Contineum Therapeutics
Members talk about Contineum Therapeutics (CTNM). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Contineum Therapeutics, newest first. Each line links the filing it comes from.
Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:CTNM on TradingView.
SEC filings and registration
SEC name
Contineum Therapeutics, Inc.
CIK
1855175
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
CTNM (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, 92121
Phone
(858) 333-5280
Shares outstanding
23,099,173 as of 2025-10-27 (10-Q filed 2025-10-30)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Contineum Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CTNM, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio